Corcept Misses Q1 Revenue Estimates, Reports Loss, Boosts Full-Year Outlook
CORT sits 64% above its 52-week low of $28.66.
Summary
Corcept Therapeutics reported Q1 revenue of $164.90 million, significantly missing analyst estimates of $192.51 million, and posted a net loss of $31.76 million (EPS -$0.30) due to increased operating expenses related to the launch of Lifyorli. This follows a challenging 2025 marked by profitability declines. Despite the quarterly shortfall, the company raised its full-year 2026 revenue guidance to $950-$1,050 million and anticipates a return to profitability in Q2 2026. The positive outlook is driven by the recent FDA approval and launch of Lifyorli for platinum-resistant ovarian cancer, as well as strong demand for Korlym. Traders will closely monitor the sales ramp-up of Lifyorli and the company's ability to achieve its revised profitability targets.
At the time of this announcement, CORT was trading at $46.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5B. The 52-week trading range was $28.66 to $91.00. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.